Hologic Inc.
Hologic Reports Q4 2025 Financial Results
Summary
Hologic, Inc. announced its financial results for the fourth quarter ended September 27, 2025, reporting a revenue of $1,049.5 million, up 6.2%. GAAP diluted EPS increased by 9.2% to $0.83, and non-GAAP diluted EPS grew 11.9% to $1.13. The company also highlighted organic revenue growth of 5.4% and noted that it is not providing financial guidance for fiscal year 2026 due to the proposed acquisition by Blackstone and TPG.
Profitelligence Alerts
Get alerts for HOLX
Be first to know when Hologic Inc. files with the SEC.
Filing Categories
Advertisement
About Hologic Inc.
Hologic Inc. is a leading global medical technology company focused on improving women's health and well-being. Its primary function is to develop, manufacture, and supply diagnostic products, medical imaging systems, and surgical products, which play crucial roles in the prevention and treatment of diseases. Hologic's key sectors include breast health, diagnostics, gynecological surgical, and skeletal health solutions. It is renowned for innovative technologies such as 3D mammography or tomosynthesis, which are significant advancements in breast cancer detection. With a commitment to enhancing healthcare quality and efficiency, Hologic operates across a diverse range of healthcare settings, from hospitals and clinics to laboratories and research facilities. Headquartered in Marlborough, Massachusetts, Hologic has established itself as a pivotal player in women's health diagnostics, contributing to its substantial market presence and influence in the global healthcare sector.
Official SEC Documents
Advertisement